Esketamine with ECT for severe depression in teens
Part of Mental health clinical trials.
This study tests whether adding a low dose of esketamine (a type of anesthesia) to modified electroconvulsive therapy (ECT) helps treat severe depression in teenagers. It aims to see if this combination works better and is safer than ECT alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 13 and 17 years old and have been diagnosed with major depression.
- You are currently in the hospital and are scheduled to get electroconvulsive therapy (ECT).
- You have completed at least primary school and can see and hear normally (including color vision).
- You have no heart problems, severe high blood pressure, or history of substance abuse.
- You have not had ECT in the last 6 months, and you don't have other major mental health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two anesthesia medicines—esketamine plus propofol versus methohexital—for people receiving ECT (electroconvulsive therapy) for severe depression. The goal is to see which anesthesia approach works better and is safer for patients during ECT.
This study compares the effectiveness of esketamine (Spravato) and another similar drug, ketamine, for adults with major depression that has not improved after trying at least two other antidepressants. It aims to find out which treatment works better.
This trial tests whether esketamine, an anesthetic, can help reduce severe depression symptoms in women having breast cancer surgery. You may qualify if you have severe depression before surgery.
This trial tests if esketamine (a nasal spray) can quickly reduce symptoms of major depression and suicidal thoughts in teenagers who need urgent hospital care.
This trial tests whether adding ketamine to electroconvulsive therapy (ECT) works better than ECT alone for people with depression that hasn't improved with at least two different antidepressants. It may offer a new option for those who have not found relief from standard treatments.
This trial tests how treatment with esketamine affects metabolism in people with depression. It may help if you have not responded to at least two standard antidepressants.
Hear when a new Esketamine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.